Getein Biotech
Market Cap
CN¥8.8b
Last Updated
2021/04/17 09:18 UTC
Data Sources
Company Financials +
Executive Summary
Getein Biotech, Inc researches, develops, produces, and sells in vitro diagnostic products in China and internationally. More Details
Rewards
Risk Analysis
Snowflake Analysis
Excellent balance sheet and fair value.
Share Price & News
How has Getein Biotech's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 603387 is not significantly more volatile than the rest of CN stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: 603387's weekly volatility (5%) has been stable over the past year.
Market Performance
7 Day Return
-0.5%
603387
-0.2%
CN Biotechs
-0.8%
CN Market
1 Year Return
-5.1%
603387
33.0%
CN Biotechs
25.0%
CN Market
Return vs Industry: 603387 underperformed the CN Biotechs industry which returned 33% over the past year.
Return vs Market: 603387 underperformed the CN Market which returned 25% over the past year.
Shareholder returns
| 603387 | Industry | Market | |
|---|---|---|---|
| 7 Day | -0.5% | -0.2% | -0.8% |
| 30 Day | -0.03% | 9.5% | -0.08% |
| 90 Day | 4.1% | 2.9% | -5.3% |
| 1 Year | -3.8%-5.1% | 33.4%33.0% | 27.0%25.0% |
| 3 Year | 11.9%8.6% | 85.6%82.7% | 29.1%22.8% |
| 5 Year | n/a | 74.7%71.4% | 30.5%21.7% |
Long-Term Price Volatility Vs. Market
How volatile is Getein Biotech's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Valuation
Is Getein Biotech undervalued compared to its fair value and its price relative to the market?
28.34x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: 603387 (CN¥34.01) is trading above our estimate of fair value (CN¥12.62)
Significantly Below Fair Value: 603387 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 603387 is good value based on its PE Ratio (28.3x) compared to the CN Biotechs industry average (55.1x).
PE vs Market: 603387 is good value based on its PE Ratio (28.3x) compared to the CN market (33.6x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 603387's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 603387 is good value based on its PB Ratio (5.1x) compared to the CN Biotechs industry average (6.3x).
Future Growth
How is Getein Biotech forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
21.8%
Forecasted annual revenue growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if 603387's forecast earnings growth is above the savings rate (3.3%).
Earnings vs Market: Insufficient data to determine if 603387's earnings are forecast to grow faster than the CN market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 603387's revenue (21.8% per year) is forecast to grow faster than the CN market (17.7% per year).
High Growth Revenue: 603387's revenue (21.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 603387's Return on Equity is forecast to be low in 3 years time (19%).
Past Performance
How has Getein Biotech performed over the past 5 years?
19.3%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 603387 has high quality earnings.
Growing Profit Margin: 603387's current net profit margins (27.6%) are lower than last year (35.1%).
Past Earnings Growth Analysis
Earnings Trend: 603387's earnings have grown by 19.3% per year over the past 5 years.
Accelerating Growth: 603387's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 603387 had negative earnings growth (-8.1%) over the past year, making it difficult to compare to the Biotechs industry average (17.7%).
Return on Equity
High ROE: 603387's Return on Equity (16.5%) is considered low.
Financial Health
How is Getein Biotech's financial position?
Financial Position Analysis
Short Term Liabilities: 603387's short term assets (CN¥1.9B) exceed its short term liabilities (CN¥526.3M).
Long Term Liabilities: 603387's short term assets (CN¥1.9B) exceed its long term liabilities (CN¥7.6M).
Debt to Equity History and Analysis
Debt Level: 603387's debt to equity ratio (15.7%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if 603387's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: 603387's debt is well covered by operating cash flow (85%).
Interest Coverage: 603387 earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Dividend
What is Getein Biotech current dividend yield, its reliability and sustainability?
1.18%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 603387's dividend (1.18%) is higher than the bottom 25% of dividend payers in the CN market (0.44%).
High Dividend: 603387's dividend (1.18%) is low compared to the top 25% of dividend payers in the CN market (1.79%).
Stability and Growth of Payments
Stable Dividend: Whilst dividend payments have been stable, 603387 has been paying a dividend for less than 10 years.
Growing Dividend: 603387's dividend payments have increased, but the company has only paid a dividend for 3 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (33.3%), 603387's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: 603387's dividends in 3 years are forecast to be well covered by earnings (27.6% payout ratio).
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
CEO
Getein Biotech has no CEO, or we have no data on them.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Getein Biotech, Inc's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Getein Biotech, Inc
- Ticker: 603387
- Exchange: SHSE
- Founded: 2002
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: CN¥8.840b
- Shares outstanding: 260.34m
- Website: https://www.bio-gp.com.cn
Number of Employees
Location
- Getein Biotech, Inc
- No.9 Bofu Road
- Luhe District
- Nanjing
- Jiangsu Province
- 211505
- China
Listings
Biography
Getein Biotech, Inc researches, develops, produces, and sells in vitro diagnostic products in China and internationally. The company provides diagnostic reagents and analyzers; calibrators; reagent raw mat...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/04/17 09:18 |
| End of Day Share Price | 2021/04/16 00:00 |
| Earnings | 2020/12/31 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.